New York, USA | March 27, 2026
LB Pharmaceuticals announced new findings from its Phase 2 NOVA-1 clinical trial, highlighting the potential of LB-102, a novel investigational antipsychotic, to deliver significant improvements in cognitive performance in patients with schizophrenia. The data, presented at the 2026 Schizophrenia International Research Society (SIRS) Congress in Florence, Italy, underscore the drug’s ability to address positive, negative, and cognitive symptoms, representing a critical advancement in neuropsychiatric drug development. As detailed in the study summary, the post hoc analysis demonstrated that improvements in cognition were statistically significant and primarily a direct effect of LB-102, rather than secondary to overall symptom improvement, marking a key differentiation from existing therapies.
Phase 2 Data Demonstrates Cognitive and Symptom Benefits
Results from the randomized, double-blind, placebo-controlled Phase 2 trial showed that LB-102 achieved statistically significant improvements across all dose levels, including a rapid onset of action within one week and sustained efficacy throughout the study period. Importantly, the therapy demonstrated dose-dependent improvements in global cognition scores, even in patients without severe baseline cognitive impairment. Additional analyses presented at SIRS highlighted improvements across the PANSS Marder factor domains, including positive symptoms, negative symptoms, disorganized thinking, anxiety/depression, and hostility, offering a comprehensive therapeutic profile. These findings suggest that LB-102 could address multiple dimensions of schizophrenia, a major unmet need in current treatment paradigms where cognitive impairment often remains inadequately treated.
Favorable Safety Profile and Differentiated Mechanism
LB-102 is a once-daily oral small molecule and a selective antagonist of D2, D3, and 5HT7 receptors, designed to provide broad efficacy with improved tolerability. The trial demonstrated a favorable safety profile, with low rates of extrapyramidal symptoms (EPS), minimal sedation, and limited gastrointestinal side effects, positioning it as a potential best-in-class antipsychotic candidate.
Advertisement
As highlighted in the clinical data, the compound builds on the pharmacological benefits of amisulpride, while addressing its limitations, enabling a more balanced profile across efficacy and safety. These attributes are particularly important in long-term psychiatric treatment, where tolerability and adherence are critical to patient outcomes.
Advancing Toward Phase 3 and Broader Indications
Building on these positive results, LB Pharmaceuticals has initiated a pivotal Phase 3 trial (NOVA-2) to further evaluate LB-102 in patients with acute schizophrenia, with cognitive performance included as a key secondary endpoint. Additional studies are underway or planned across bipolar depression, major depressive disorder (MDD), and other neuropsychiatric conditions, reflecting the compound’s broad therapeutic potential.
The company is also exploring expansion into Alzheimer’s disease psychosis and agitation, highlighting the versatility of the drug’s mechanism. As schizophrenia continues to impose a significant burden on patients and healthcare systems worldwide, innovations like LB-102 offer the potential to transform treatment standards by addressing not only core symptoms but also functional and cognitive impairments that impact daily life.
Advancing Toward Phase 3 and Broader Indications
Building on these positive results, LB Pharmaceuticals has initiated a pivotal Phase 3 trial (NOVA-2) to further evaluate LB-102 in patients with acute schizophrenia, with cognitive performance included as a key secondary endpoint. Additional studies are underway or planned across bipolar depression, major depressive disorder (MDD), and other neuropsychiatric conditions, reflecting the compound’s broad therapeutic potential.
The company is also exploring expansion into Alzheimer’s disease psychosis and agitation, highlighting the versatility of the drug’s mechanism. As schizophrenia continues to impose a significant burden on patients and healthcare systems worldwide, innovations like LB-102 offer the potential to transform treatment standards by addressing not only core symptoms but also functional and cognitive impairments that impact daily life.
Transforming Neuropsychiatric Treatment Landscape
Schizophrenia remains a complex and debilitating disorder, with current therapies often failing to adequately address cognitive dysfunction, which is a major determinant of long-term functional outcomes. The data presented at SIRS 2026 position LB-102 as a next-generation antipsychotic capable of delivering multi-dimensional clinical benefits, including rapid symptom control, cognitive enhancement, and improved tolerability. By combining innovative receptor targeting, strong clinical efficacy, and patient-centric outcomes, LB Pharmaceuticals is advancing a promising solution to one of the most challenging areas in mental health treatment. As the drug progresses through late-stage development, it holds significant potential to reshape the future of schizophrenia care and neuropsychiatric therapeutics.
Source: LB Pharmaceuticals press release
